S A Jabbour

Summary

Affiliation: Thomas Jefferson University
Country: USA

Publications

  1. doi request reprint Dapagliflozin Is Effective as Add-on Therapy to Sitagliptin With or Without Metformin: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study
    Serge A Jabbour
    Corresponding author Serge A Jabbour
    Diabetes Care 37:740-50. 2014
  2. doi request reprint SGLT2 inhibitors to control glycemia in type 2 diabetes mellitus: a new approach to an old problem
    Serge A Jabbour
    Department of Medicine, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA
    Postgrad Med 126:111-7. 2014
  3. doi request reprint Targeting renal glucose reabsorption for the treatment of type 2 diabetes mellitus using the SGLT2 inhibitor dapagliflozin
    Serge A Jabbour
    Division of Endocrinology, Diabetes and Metabolic Diseases, Jefferson Medical College of Thomas Jefferson University, Philadelphia, PA 19107, USA
    Postgrad Med 124:62-73. 2012
  4. doi request reprint Advantages of extended-release metformin in patients with type 2 diabetes mellitus
    Serge Jabbour
    Department of Medicine, Division of Endocrinology, Diabetes, and Metabolic Diseases, Jefferson Medical College of Thomas Jefferson University, Philadelphia, PA 19107, USA
    Postgrad Med 123:15-23. 2011
  5. doi request reprint Skin manifestations of hormone-secreting tumors
    Serge A Jabbour
    Division of Endocrinology, Diabetes and Metabolic Diseases, Department of Medicine, Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
    Dermatol Ther 23:643-50. 2010
  6. doi request reprint Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes
    S A Jabbour
    Division of Endocrinology, Diabetes and Metabolic Diseases, Department of Medicine, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA 19107, USA
    Int J Clin Pract 62:1279-84. 2008
  7. ncbi request reprint Rare syndromes
    Serge A Jabbour
    Division of Endocrinology, Diabetes and Metabolic Diseases, Thomas Jefferson University, Philadelphia, PA 19107, USA
    Clin Dermatol 24:299-316. 2006
  8. ncbi request reprint Cutaneous manifestations of endocrine disorders: a guide for dermatologists
    Serge A Jabbour
    Division of Endocrinology, Diabetes and Metabolism, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
    Am J Clin Dermatol 4:315-31. 2003
  9. ncbi request reprint Insulin resistance, diabetes and cardiovascular risk: approaches to treatment
    Daniel E Rosenberg
    Division of Endocrinology, Diabetes and Metabolic Diseases, Department of Medicine, Jefferson Medical College of Thomas Jefferson University, Philadelphia, PA 19107, USA
    Diabetes Obes Metab 7:642-53. 2005
  10. ncbi request reprint Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study
    Lawrence Blonde
    Department of Internal Medicine, Oschner Clinic Foundation, New Orleans, LA, USA
    Curr Med Res Opin 20:565-72. 2004

Detail Information

Publications10

  1. doi request reprint Dapagliflozin Is Effective as Add-on Therapy to Sitagliptin With or Without Metformin: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study
    Serge A Jabbour
    Corresponding author Serge A Jabbour
    Diabetes Care 37:740-50. 2014
    ..CONCLUSIONS These results suggest that in patients with type 2 diabetes, inadequately controlled on sitagliptin with or without metformin, add-on treatment with dapagliflozin provides additional clinical benefit and is well tolerated. ..
  2. doi request reprint SGLT2 inhibitors to control glycemia in type 2 diabetes mellitus: a new approach to an old problem
    Serge A Jabbour
    Department of Medicine, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA
    Postgrad Med 126:111-7. 2014
    ..The SGLT2 inhibitors have become a valuable addition to the armory of drugs used to treat patients with type 2 diabetes mellitus, and several agents within the class are currently under investigation in phase III clinical trials. ..
  3. doi request reprint Targeting renal glucose reabsorption for the treatment of type 2 diabetes mellitus using the SGLT2 inhibitor dapagliflozin
    Serge A Jabbour
    Division of Endocrinology, Diabetes and Metabolic Diseases, Jefferson Medical College of Thomas Jefferson University, Philadelphia, PA 19107, USA
    Postgrad Med 124:62-73. 2012
    ..As such, dapagliflozin promises to become an important adjunctive therapy for comprehensive treatment of T2DM...
  4. doi request reprint Advantages of extended-release metformin in patients with type 2 diabetes mellitus
    Serge Jabbour
    Department of Medicine, Division of Endocrinology, Diabetes, and Metabolic Diseases, Jefferson Medical College of Thomas Jefferson University, Philadelphia, PA 19107, USA
    Postgrad Med 123:15-23. 2011
    ....
  5. doi request reprint Skin manifestations of hormone-secreting tumors
    Serge A Jabbour
    Division of Endocrinology, Diabetes and Metabolic Diseases, Department of Medicine, Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
    Dermatol Ther 23:643-50. 2010
    ..We will focus on clinical manifestations, mainly cutaneous, followed by a brief discussion on how to make the diagnosis of each condition in addition to treatment options...
  6. doi request reprint Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes
    S A Jabbour
    Division of Endocrinology, Diabetes and Metabolic Diseases, Department of Medicine, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA 19107, USA
    Int J Clin Pract 62:1279-84. 2008
    ..Competitive inhibitors of SGLT2 that provoke the renal excretion of glucose have been discovered, thereby providing a unique mechanism to potentially lower the elevated blood glucose levels in patients with diabetes...
  7. ncbi request reprint Rare syndromes
    Serge A Jabbour
    Division of Endocrinology, Diabetes and Metabolic Diseases, Thomas Jefferson University, Philadelphia, PA 19107, USA
    Clin Dermatol 24:299-316. 2006
    ..Patients present with urticaria pigmentosa, mastocytoma, or diffuse cutaneous mastocytosis. Systemic involvement may be gastronintestinal, hematologic, neurologic, and skeletal...
  8. ncbi request reprint Cutaneous manifestations of endocrine disorders: a guide for dermatologists
    Serge A Jabbour
    Division of Endocrinology, Diabetes and Metabolism, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
    Am J Clin Dermatol 4:315-31. 2003
    ..Some of the cutaneous manifestations of diabetes mellitus include necrobiosis lipoidica diabeticorum, diabetic dermopathy, scleredema adultorum and acanthosis nigricans...
  9. ncbi request reprint Insulin resistance, diabetes and cardiovascular risk: approaches to treatment
    Daniel E Rosenberg
    Division of Endocrinology, Diabetes and Metabolic Diseases, Department of Medicine, Jefferson Medical College of Thomas Jefferson University, Philadelphia, PA 19107, USA
    Diabetes Obes Metab 7:642-53. 2005
    ..As macrovascular disease is the major cause of morbidity and mortality, an early, aggressive, multi-factorial approach to treatment of the metabolic syndrome and diabetes is vital to prevent adverse cardiac outcomes...
  10. ncbi request reprint Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study
    Lawrence Blonde
    Department of Internal Medicine, Oschner Clinic Foundation, New Orleans, LA, USA
    Curr Med Res Opin 20:565-72. 2004
    ..This retrospective chart review examined the overall gastrointestinal (GI) tolerability of both formulations...